⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
EBS News
Emergent Biosolutions, Inc.
Form 8-K
sec.gov
EBS
Emergent BioSolutions Reports First Quarter 2026 Financial Results
globenewswire.com
EBS
Emergent BioSolutions Receives Approval from Singapore Health Sciences Authority for Expanded Indication of ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) to Include Mpox
globenewswire.com
EBS
Form 8-K
sec.gov
EBS
Emergent BioSolutions Secures Long-Term Strategic Manufacturing Contract with SAB Biotherapeutics to Advance Type 1 Diabetes Candidate, SAB-142
globenewswire.com
SABS
EBS
Emergent BioSolutions Partners with Professional Baseball Player Davis Schneider to Raise Awareness of NARCAN® Nasal Spray Among Canadians and Help Save Lives
globenewswire.com
EBS
Emergent BioSolutions and Substipharm Biologics Announce Strategic Manufacturing Partnership to Support Japanese Encephalitis Vaccine in the United States
globenewswire.com
EBS
DUAL-PATHWAY BLOCKADE THERAPY OFFERS HOPE FOR RARE, HARD-TO-TREAT GYNAECOLOGICAL CLEAR CELL CANCERS
prnewswire.com
MRK
EBS
Form 8-K
sec.gov
EBS
Emergent BioSolutions to Report First Quarter 2026 Financial Results on April 30, 2026
globenewswire.com
EBS